Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;81(4):647-679.
doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24.

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Fabrizio Cantini  1 , Laura Niccoli  2 , Carlotta Nannini  2 , Daniela Matarrese  3 , Massimo Edoardo Di Natale  4 , Pamela Lotti  5 , Donatella Aquilini  6 , Giancarlo Landini  7 , Barbara Cimolato  8 , Massimo Antonio Di Pietro  9 , Michele Trezzi  10 , Paolo Stobbione  11 , Gabriele Frausini  12 , Assunta Navarra  13 , Emanuele Nicastri  14 , Giovanni Sotgiu  15 , Delia Goletti  16
Affiliations
Comment

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Fabrizio Cantini et al. J Infect. 2020 Oct.

Abstract

  1. •

    Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry.

  2. •

    In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate.

  3. •

    Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia.

  4. •

    Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab.

  5. •

    Baricitinib used for 2 weeks was not associated with serious adverse events.

Keywords: Baricitinib; COVID-19; JAK1/2; Pneumonia; Retrospective study; SARS-Co-V2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All Authors have nothing to disclose.

Figures

Image, graphical abstract
Graphical abstract
See this image and copyright information in PMC

Comment on

References

    1. Cantini F., Niccoli L., Matarrese D., Nicastri E., Stobbione P., Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020 doi: 10.1016/j.jinf.2020.04.017. Apr 23Epub ahead of print] - DOI - PMC - PubMed
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Sun X., Wang T., Cai D. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 doi: 10.1016/j.cytogfr.2020.04.002. Apr. 25. - DOI - PMC - PubMed
    1. Adachi T., Chong J.M., Nakajima N. Clinicopathological and immunohistochemical findings from autopsy of patient with COVID-19, Japan. Emerg Infect Dis. 2020;26(9) doi: 10.3201/eid2609.201353. May 15[Epub ahead of print] - DOI - PMC - PubMed
    1. Stebbing J., Phelan A., Griffin I., Tucker C., Oechsle O., Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020. 2020 doi: 10.1016/51473-3099(20)30132-8. Published online February 27https//doi.org/ - DOI - PMC - PubMed